Alex Carchidi
Alex Carchidi is a contributing Healthcare and Cryptocurrency Analyst at The Motley Fool, covering publicly traded companies and investments in the biotech, pharma, cannabis, and digital asset industries. Prior to The Motley Fool, Alex was a bench scientist and later a science writer at several biopharma companies, and started his career as a researcher at the Ragon Institute of MGH, MIT, and Harvard. He holds a B.A. in Biology and a B.A. in Philosophy from Boston University, and an MBA with a concentration in Finance from the Isenberg School of Business at the University of Massachusetts, Amherst. In his spare time, Alex enjoys traveling in Latin America and exploring the food scene of Greater Boston.
Recent Articles by Alex Carchidi

Where Will Teladoc Health Be in 3 Years?

Is Pfizer a Millionaire Maker?

Is Bristol-Myers Squibb Stock a Millionaire Maker?

Is Medical Properties Trust Stock a Buy?

Warning: This Skyrocketing Stock Has a Hidden Risk

Is Novo Nordisk Stock a Buy?

Is Tilray Brands Stock a Buy?

Where Will Bristol Myers Squibb Be in 5 Years?

Investing in Pharma Stocks? Check These 3 Things First
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.